GlassScriptPhysician profile
Amy M Adams
NPI 1306416268
$4,511.20
in general payments reported to CMS, 2019-2025
18 companies · $784 in 2025
The $784 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $693 · 2023: $1,573 · 2024: $1,332 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $961.70 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $471.75 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $416.61 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $398.88 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $396.40 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $367.83 | 2022-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.29 | 2022-2025 | Caplyta |
| Lundbeck LLC | $259.79 | 2021-2025 | Rexulti |
| Abbvie INC. | $249.22 | 2021-2025 | Vraylar |
| Indivior INC. | $231.16 | 2022-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $109.77 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $74.05 | 2023-2025 | Auvelity |
| Corium, LLC | $63.94 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $57.86 | 2022 | |
| Biogen, INC. | $44.83 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $42.34 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $40.86 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $27.92 | 2021-2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.